{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:21:45Z","timestamp":1792012905268,"version":"4.4.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020343","name":"Biointerfaces Institute, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113743","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:27:17Z","timestamp":1744878437000},"page":"113743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Local controlled release of stabilized monoclonal antibodies"],"prefix":"10.1016","volume":"383","author":[{"given":"Rae Sung","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzar A.","family":"Mujeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Kadiyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Pisupati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jamison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Haggag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Antonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113743_bb0005","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acschemneuro.8b00320","article-title":"New 2017 Data and statistics for pharmaceutical products","volume":"9","author":"Lindsley","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.addr.2017.06.002","article-title":"Covalent nano delivery systems for selective imaging and treatment of brain tumors","volume":"113","author":"Ljubimova","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113743_bb0020","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1517\/17425247.2011.628983","article-title":"Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood\u2013retinal barrier","volume":"8","author":"Hosoya","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.113743_bb0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113743_bb0030","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.addr.2005.09.003","article-title":"Wet age-related macular degeneration","volume":"57","author":"Kulkarni","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113743_bb0035","series-title":"Gene-and Cell-Based Treatment Strategies for the Eye","author":"Rakoczy","year":"2015"},{"key":"10.1016\/j.jconrel.2025.113743_bb0040","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd3790","article-title":"Wet AMD market","volume":"11","author":"Syed","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113743_bb0045","series-title":"(ranibizumab injection) [FDA package insert]","author":"Lucentis(R)","year":"2014"},{"key":"10.1016\/j.jconrel.2025.113743_bb0050","series-title":"(aflibercept) [FDA Package Insert]","author":"Eylea(TM)","year":"2011"},{"key":"10.1016\/j.jconrel.2025.113743_bb0055","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113743_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2025.113743_bb0065","first-page":"1281","article-title":"Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life, Graefe\u2019s archive for","volume":"251","author":"Droege","year":"2013","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0070","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1080\/10717544.2018.1474967","article-title":"Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization","volume":"25","author":"Mu","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.113743_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14837","article-title":"Long-acting protein drugs for the treatment of ocular diseases","volume":"8","author":"Ghosh","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113743_bb0080","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbm.a.36424","article-title":"Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment","volume":"106","author":"Badiee","year":"2018","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2025.113743_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrclinonc.2012.204","article-title":"Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?,","volume":"10","author":"Tanaka","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2017.07.006","article-title":"Evolutionary basis of a new gene-and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients","volume":"189","author":"Lowenstein","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11764-017-0602-7","article-title":"Life beyond a diagnosis of glioblastoma: a systematic review of the literature","volume":"11","author":"Gately","year":"2017","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.jconrel.2025.113743_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2025.113743_bb0105","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-017-0492-y","article-title":"Clinical trials investigating immune checkpoint blockade in glioblastoma","volume":"18","author":"Maxwell","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma,","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.exer.2018.01.010","article-title":"Topical drug delivery devices: a review","volume":"168","author":"Bertens","year":"2018","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0125","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1245\/s10434-008-0048-2","article-title":"Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience","volume":"15","author":"Attenello","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0130","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.2174\/1381612822666160217141049","article-title":"The production of solid dosage forms from non-degradable polymers","volume":"22","author":"Major","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2025.113743_bb0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13346-011-0024-4","article-title":"Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections","volume":"1","author":"Friend","year":"2011","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40256-018-0265-4","article-title":"Drug-eluting stents for treatment of peripheral artery disease,","volume":"18","author":"Abdullah","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.jconrel.2025.113743_bb0145","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A polymer-coated, paclitaxel-eluting stent (eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial","volume":"392","author":"Gray","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.113743_bb0150","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2106\/JBJS.N.00918","article-title":"An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial","volume":"97","author":"Bodick","year":"2015","journal-title":"JBJS"},{"key":"10.1016\/j.jconrel.2025.113743_bb0155","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1026498209874","article-title":"Protein instability in poly (lactic-co-glycolic acid) microparticles","volume":"17","author":"van de Weert","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jconrel.2009.05.009","article-title":"An injectable drug delivery platform for sustained combination therapy","volume":"138","author":"Baumann","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0165","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijpharm.2012.01.035","article-title":"In vitro sustained release of bioactive anti-NogoA, a molecule in clinical development for treatment of spinal cord injury","volume":"426","author":"Stanwick","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113743_bb0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcis.2003.08.072","article-title":"Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres","volume":"271","author":"Wang","year":"2004","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.04.043","article-title":"Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer","volume":"61","author":"Rahimian","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113743_bb0180","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2012.03.014","article-title":"Two-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies","volume":"160","author":"Koutsopoulos","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/toxsci\/52.1.101","article-title":"Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation","volume":"52","author":"Mordenti","year":"1999","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"10.1016\/j.jconrel.2025.113743_bb0195","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s13346-016-0298-7","article-title":"In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device,","volume":"6","author":"Lance","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2004.09.025","article-title":"Hyaluronic acid hydrogel as Nogo-66 receptor antibody delivery system for the repairing of injured rat brain: in vitro","volume":"102","author":"Tian","year":"2005","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0205","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1002\/adfm.201000907","article-title":"Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide","volume":"20","author":"Andrew","year":"2010","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113743_bb0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1021\/bm301352x","article-title":"Protein-polyanion interactions for the controlled release of monoclonal antibodies","volume":"14","author":"Schweizer","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2025.113743_bb0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1208\/s12249-016-0548-5","article-title":"Hot melt extrusion for sustained protein release: matrix erosion and in vitro release of PLGA-based implants","volume":"18","author":"Coss\u00e9","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2025.113743_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.10.026","article-title":"Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model","volume":"244","author":"Adamson","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0225","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113743_bb0230","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1021\/acs.biomac.7b00587","article-title":"Controlled antibody release from degradable Thermoresponsive hydrogels cross-linked by Diels-Alder chemistry","volume":"18","author":"Gregoritza","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2025.113743_bb0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.actbio.2018.07.040","article-title":"Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity","volume":"78","author":"Sousa","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.113743_bb0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11095-018-2368-7","article-title":"Formulation stabilization and disaggregation of bevacizumab, ranibizumab and aflibercept in dilute solutions","volume":"35","author":"Giannos","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0245","series-title":"[FDA Package Insert], Irvine, CA, Allergan","author":"Ozurdex(R)","year":"2014"},{"key":"10.1016\/j.jconrel.2025.113743_bb0250","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1007513425337","article-title":"Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives","volume":"17","author":"Zhu","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/71916","article-title":"Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)","volume":"18","author":"Zhu","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0260","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2007.05.016","article-title":"Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF\/poly(DL-lactic-co-glycolic acid) implants","volume":"122","author":"Zhong","year":"2007","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0265","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.exer.2018.05.027","article-title":"A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies","volume":"174","author":"Li","year":"2018","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1167\/iovs.17-22897","article-title":"Aflibercept action in a rabbit model of chronic retinal neovascularization: reversible inhibition of pathologic leakage with dose-dependent duration","volume":"59","author":"Cao","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0275","series-title":"Animal Models of Brain Tumors, Humana Totowa, NJ","author":"Murillo","year":"2013"},{"key":"10.1016\/j.jconrel.2025.113743_bb0280","series-title":"(bevacizumab), labeling text, Label Amend","first-page":"1","year":"2009"},{"key":"10.1016\/j.jconrel.2025.113743_bb0285","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0290","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pro.3","article-title":"Effect of trehalose on protein structure","volume":"18","author":"Jain","year":"2009","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0295","series-title":"Trehalose and Protein Stability, Current Protocols in Protein Science","first-page":"4","author":"Jain","year":"2010"},{"key":"10.1016\/j.jconrel.2025.113743_bb0300","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2025.113743_bb0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0310","series-title":"Oncologic Drugs Advisory Committee","author":"FDA","year":"2015"},{"key":"10.1016\/j.jconrel.2025.113743_bb0315","series-title":"(ipilimumab), [FDA Package Insert]","author":"Yervoy(R)","year":"2011"},{"key":"10.1016\/j.jconrel.2025.113743_bb0320","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113743_bb0325","series-title":"Long-Acting Drug Delivery Systems","first-page":"61","article-title":"3 - long-acting drug delivery systems for ocular therapies","author":"Waite","year":"2022"},{"key":"10.1016\/j.jconrel.2025.113743_bb0330","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/17425247.2022.2108397","article-title":"Long-acting ocular drug delivery technologies with clinical precedent","volume":"19","author":"O\u2019Brien Laramy","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.113743_bb0335","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/pharmaceutics15061746","article-title":"Recent advances of ocular drug delivery systems: prominence of ocular implants for chronic eye diseases","volume":"15","author":"Mostafa","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113743_bb0340","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s10792-023-02637-x","article-title":"Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics","volume":"43","author":"Cong","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jot.2019.04.002","article-title":"Bevacizumab tested for treatment of knee osteoarthritis via inhibition of synovial vascular hyperplasia in rabbits","volume":"19","author":"Li","year":"2019","journal-title":"J. Orthopaedic Transl."},{"key":"10.1016\/j.jconrel.2025.113743_bb0350","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13075-014-0427-y","article-title":"Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis","volume":"16","author":"Nagai","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2025.113743_bb0355","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40123-023-00843-5","article-title":"Clinical trials and future outlooks of the port delivery system with Ranibizumab: a narrative review","volume":"13","author":"Lowater","year":"2024","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.jconrel.2025.113743_bb0360","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/786870","article-title":"Anti-VEGF treatment strategies for wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119632","article-title":"Overview of key molecular and pharmacological targets for diabetes and associated diseases","volume":"278","author":"Shahcheraghi","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0370","first-page":"205","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration, Turkish","volume":"47","author":"Polat","year":"2017","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0375","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pharmaceutics10010021","article-title":"Extended duration vascular endothelial growth factor inhibition in the eye: failures, successes, and future possibilities","volume":"10","author":"Stewart","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113743_bb0380","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/1061186X.2015.1052073","article-title":"Recent developments in ocular drug delivery","volume":"23","author":"Chen","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2025.113743_bb0385","first-page":"2277","article-title":"Interim results of a dose escalation study of NT-503 encapsulated cell therapy for the treatment of choroidal neovascularization in AMD","volume":"56","author":"Loewenstein","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.3.3.8","article-title":"One-year feasibility study of replenish MicroPump for intravitreal drug delivery: a pilot study","volume":"3","author":"Guti\u00e9rrez-Hern\u00e1ndez","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0395","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2025.113743_bb0400","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2025.113743_bb0405","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1016\/j.biomaterials.2012.06.013","article-title":"The microclimate pH in poly(D,L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation","volume":"33","author":"Liu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113743_bb0410","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijpharm.2014.04.063","article-title":"Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres","volume":"470","author":"Marquette","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113743_bb0415","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0168-3659(98)00061-3","article-title":"Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy","volume":"55","author":"Zhou","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0420","series-title":"Microparticulate Systems for the Delivery of Proteins and Vaccines","first-page":"1","article-title":"Stability of proteins and their delivery from biodegradable polymer microspheres","author":"Schwendeman","year":"1996"},{"key":"10.1016\/j.jconrel.2025.113743_bb0425","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1002\/anie.201206387","article-title":"Self-healing microencapsulation of biomacromolecules without organic solvents","volume":"51","author":"Reinhold","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.113743_bb0430","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s11095-007-9430-1","article-title":"Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor","volume":"25","author":"Desai","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121046","article-title":"Matrix metalloproteinase 2 is a target of the RAN-GTP pathway and mediates migration, invasion and metastasis in human breast cancer","volume":"310","author":"El-Tanani","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0440","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0142-9612(01)00101-6","article-title":"Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants","volume":"23","author":"Kang","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113743_bb0445","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejpb.2008.03.007","article-title":"Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants","volume":"70","author":"Desai","year":"2008","journal-title":"Eur. J. Pharmaceut. Biopharmaceut."},{"key":"10.1016\/j.jconrel.2025.113743_bb0450","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/pharmaceutics10040263","article-title":"A comprehensive map of FDA-approved pharmaceutical products","volume":"10","author":"Zhong","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113743_bb0455","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2014.05.057","article-title":"Injectable controlled release depots for large molecules","volume":"190","author":"Schwendeman","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113743_bb0460","series-title":"Merck Veterinary Manual","article-title":"Management of Rabbits","author":"Mayer","year":"2021"},{"key":"10.1016\/j.jconrel.2025.113743_bb0465","first-page":"475","article-title":"Effect of dexamethasone intravitreal implant in a corneal graft rejection, international","volume":"9","author":"Yesilirmak","year":"2016","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0470","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008280","article-title":"Efficacy and safety of bevacizumab treatment for refractory brain edema: case report","volume":"96","author":"Meng","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.jconrel.2025.113743_bb0475","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.113743_bb0480","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11912-004-0019-0","article-title":"Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides","volume":"6","author":"Krieg","year":"2004","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.jconrel.2025.113743_bb0485","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.2741\/934","article-title":"CpG-oligonucleotides for cancer immunotherapy\u202f: review of the literature and potential applications in malignant glioma","volume":"8","author":"Carpentier","year":"2003","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0490","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ijpharm.2015.09.062","article-title":"Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma","volume":"495","author":"Lollo","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113743_bb0495","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0163-7258(03)00014-7","article-title":"Current and future strategies for the treatment of malignant brain tumors","volume":"98","author":"Castro","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.113743_bb0500","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1158\/1078-0432.CCR-14-0820","article-title":"Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier!","volume":"20","author":"Castro","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.jconrel.2025.113743_bb0505","first-page":"2469","article-title":"Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs","volume":"6","author":"Carpentier","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0510","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/glia.20401","article-title":"Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors","volume":"54","author":"El Andaloussi","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.jconrel.2025.113743_bb0515","first-page":"1365","article-title":"High-density lipoprotein-mimicking Nanodiscs for chemo-immunotherapy against glioblastoma Multiforme","volume":"13","author":"Kadiyala","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113743_bb0520","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1023\/A:1025785505977","article-title":"Drug delivery and transport to solid tumors","volume":"20","author":"Jang","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0525","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-3565(24)34976-6","article-title":"Determinants of paclitaxel penetration and accumulation in human solid tumor","volume":"290","author":"Kuh","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2025.113743_bb0530","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CJI.0b013e3181c01fcb","article-title":"Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy","volume":"33","author":"Mangsbo","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2025.113743_bb0535","first-page":"2375","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol.","volume":"26","author":"Naidoo","year":"2015"},{"key":"10.1016\/j.jconrel.2025.113743_bb0540","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113743_bb0545","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/IAE.0000000000000476","article-title":"Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections","volume":"35","author":"Pang","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2025.113743_bb0550","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1167\/iovs.16-21334","article-title":"Evaluation of the toxicity of Intravitreally injected PLGA microspheres and rods in monkeys and rabbits: effects of depot size on inflammatory response","volume":"58","author":"Thackaberry","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0555","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/0009-2509(91)80036-X","article-title":"Drugs released from polymers: diffusion and elimination in brain tissue","volume":"46","author":"Saltzman","year":"1991","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jconrel.2025.113743_bb0560","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/A:1011911912174","article-title":"Localized delivery of proteins in the brain: can transport be customized?","volume":"15","author":"Haller","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113743_bb0565","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01060215","article-title":"Distribution of drugs following controlled delivery to the brain interstitium","volume":"26","author":"Mak","year":"1995","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2025.113743_bb0570","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2025.113743_bb0575","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:22:10Z","timestamp":1762269730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":115,"alternative-id":["S0168365925003633"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113743","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local controlled release of stabilized monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113743"}}